Free Trial
Debjit Chattopadhyay

Debjit Chattopadhyay Analyst Performance

Senior Managing Director at Guggenheim

Debjit Chattopadhyay is a stock analyst at Guggenheim focused in the medical sector, covering 50 publicly traded companies. Over the past year, Debjit Chattopadhyay has issued 36 stock ratings, including strong buy, buy, and hold recommendations. While full access to Debjit Chattopadhyay's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Debjit Chattopadhyay's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
378 Last 11 Years
Buy Recommendations
90.13% 338 Buy Ratings
Companies Covered
50 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.3%1 ratings
Buy89.9%337 ratings
Hold9.9%37 ratings
Sell0.0%0 ratings

Out of 375 total stock ratings issued by Debjit Chattopadhyay at Guggenheim, the majority (89.9%) have been Buy recommendations, followed by 9.9% Hold and 0.3% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
98.0% of companies on NASDAQ
49 companies
OTCMKTS
2.0% of companies on OTCMKTS
1 company

Debjit Chattopadhyay, an analyst at Guggenheim, currently covers 50 companies listed on NASDAQ and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
48 companies
96.0%
Miscellaneous
1 company
2.0%
Manufacturing
1 company
2.0%

Debjit Chattopadhyay of Guggenheim specializes in stock coverage within the Medical sector, with additional focus on and Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
33 companies
66.0%
MED - DRUGS
8 companies
16.0%
BIOTECHNOLOGY
2 companies
4.0%
PHARMACEUTICAL PREPARATIONS
2 companies
4.0%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
2 companies
4.0%
Miscellaneous
1 company
2.0%
MED PRODUCTS
1 company
2.0%
DIAGNOSTIC SUBSTANCES
1 company
2.0%

Debjit Chattopadhyay's Ratings History at Guggenheim

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
5/8/2026Lower Price Target$26.13$43.00Buy
MSLE
Satellos Bioscience
4/28/2026Initiated Coverage$7.16$23.00Buy
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
4/2/2026Downgrade$39.71Hold
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3/20/2026Initiated Coverage$7.12$26.00Buy
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
3/4/2026Boost Price Target$44.18$58.00Buy
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2/25/2026Boost Price Target$270.43$284.00Buy
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2/25/2026Lower Price Target$61.51$86.00Buy
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2/19/2026Boost Price Target$35.76$45.00Buy
PepGen, Inc. stock logo
PEPG
PepGen
2/18/2026Boost Price Target$6.79$7.00Buy
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
2/11/2026Upgrade$10.80Strong-Buy
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
2/10/2026Initiated Coverage$10.82$20.00Buy
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1/5/2026Lower Price Target$23.60$52.00Buy
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
12/19/2025Reiterated Rating$40.62$46.00Buy
Rezolute, Inc. stock logo
RZLT
Rezolute
12/12/2025Lower Price Target$1.40$6.00Buy
Pharvaris N.V. stock logo
PHVS
Pharvaris
12/4/2025Boost Price Target$29.36$39.00Buy
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
11/18/2025Boost Price Target$28.09$43.00Buy
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
11/5/2025Lower Price Target$18.35$19.00Buy
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
10/27/2025Downgrade$14.39Neutral
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
10/17/2025Set Price Target$188.33$224.00Buy
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
10/15/2025Initiated Coverage$8.50$30.00Buy
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
10/15/2025Initiated Coverage$8.77$30.00Buy
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
10/6/2025Reiterated Rating$23.23$28.00Buy
uniQure N.V. stock logo
QURE
uniQure
9/25/2025Boost Price Target$47.50$95.00Buy
PepGen, Inc. stock logo
PEPG
PepGen
9/24/2025Reiterated Rating$1.95$6.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
9/23/2025Boost Price Target$61.36$92.00Buy
Rezolute, Inc. stock logo
RZLT
Rezolute
9/22/2025Reiterated Rating$7.70$15.00Buy
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
9/15/2025Reiterated Rating$17.39$22.00Buy
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
9/15/2025Boost Price Target$23.30$34.00Buy
PepGen, Inc. stock logo
PEPG
PepGen
9/9/2025Initiated Coverage$1.49$6.00Buy
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
8/27/2025Reiterated Rating$69.77$106.00Buy
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
8/13/2025Reiterated Rating$10.86$14.00Buy
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
8/7/2025Boost Price Target$80.99$106.00Buy
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
8/6/2025Boost Price Target$61.27$106.00Buy
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
8/6/2025Lower Price Target$387.47$546.00Buy
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
6/20/2025Reiterated Rating$36.88$64.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
6/18/2025Reiterated Rating$11.00$50.00Buy
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
5/12/2025Lower Price Target$8.71$45.00Buy
uniQure N.V. stock logo
QURE
uniQure
5/12/2025Reiterated Rating$12.76$28.00Buy
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
5/8/2025Boost Price Target$78.63$97.00Buy
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
5/7/2025Lower Price Target$136.13$189.00Buy
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th... (Ad)

After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall of Fame Trader Jon Najarian now says EVERYONE is missing an even bigger story about the SpaceX IPO… That it's just the start of an Elon Musk $44 trillion "Superconvergence…" An event that could kick off as soon as June 9th.tc pixel

Click here now to watch hall of fame trader Jon Najarian's full prediction.
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
5/7/2025Lower Price Target$15.70$55.00Buy
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
5/7/2025Lower Price Target$37.57$98.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
5/1/2025Lower Price Target$31.98$64.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
4/3/2025Reiterated Rating$27.98Buy
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3/28/2025Reiterated Rating$67.39$81.00Buy
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
3/26/2025Reiterated Rating$14.83$28.00Buy
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2/27/2025Reiterated Rating$29.04$78.00Buy
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
2/25/2025Initiated Coverage$11.33$19.00Buy
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
2/10/2025Reiterated Rating$19.03Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
1/24/2025Reiterated Rating$13.50Buy